ArticleEuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology2021
Long-term outcomes of percutaneous coronary intervention for in-stent restenosis among Medicare beneficiaries.
Article in EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07736313 (Does PCSK9 Inhibitor on Top of High Intensity Statin Impact Liver Steatosis Assessed by FibroScan in Diabetic Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndromes?), which is not on this map. Cited by 41 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Does PCSK9 Inhibitor on Top of High Intensity Statin Impact Liver Steatosis Assessed by FibroScan in Diabetic Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndromes?
Open the trial in the graphWho cites it
41 citing papers in PubMed, 5 syntheses or guidelines pooled it, 70 citations in OpenAlex.
- Drug-coated balloons in coronary in-stent restenosis: a systematic review and meta-analysis comparing sirolimus and biolimus with paclitaxel platforms.Cardiovascular intervention and therapeutics · 2026Pooled it
- Limus- versus paclitaxel-coated balloons for coronary in-stent restenosis: meta-analysis of randomized controlled trials.Cardiovascular intervention and therapeutics · 2026Pooled it
- Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in patients after percutaneous coronary intervention: a systematic review and meta-analysis.Frontiers in cardiovascular medicine · 2025Pooled it
- Risk Factors and Incidence for In-Stent Restenosis with Drug-Eluting Stent: A Systematic Review and Meta-Analysis.Reviews in cardiovascular medicine · 2024Pooled it
- Outcomes of Percutaneous Coronary Intervention for In-Stent Restenosis Versus De Novo Lesions: A Meta-Analysis.Journal of the American Heart Association · 2023Pooled it
- Safety and Efficacy of Cobalt Chromium Everolimus-Eluting Stents for Treatment of In-Stent Restenosis: An ILUMIEN IV Substudy.Journal of the American Heart Association · 2025Trial
- Effects of exenatide on coronary stent's endothelialization in subjects with type 2 diabetes: a randomized controlled trial. The Rebuild study.Cardiovascular diabetology · 2023Trial
- Molecular phenotyping withEuropean journal of nuclear medicine and molecular imaging · 2026Article
- Development of a Risk Stratification Model for Coronary In-Stent Restenosis Based on Clinical, Laboratory, and Procedural Factors: A Case-Control Study.Journal of clinical medicine · 2026Article
- Real-World Usage of a Paclitaxel-Coated Balloon With Urea Compared With Other Contemporary Drug-Coated Balloons: A 2-Year Analysis From SCAAR in Over 6000 Patients.Journal of the American Heart Association · 2026Observational
- Patient-Specific 3D Coronary Reconstruction and Computational Simulations to Guide Drug-Coated Balloon Intervention: First-in-Human Experience.JACC. Case reports · 2026Article
- Coptis chinensis extracellular vesicles loaded with CA1-siRNA promote endothelial repair and stent restenosis therapy by regulating the PADI2 and NF-κB pathway.Journal of nanobiotechnology · 2026Article
- Drug-Coated Balloons Beyond In-Stent Restenosis.Reviews in cardiovascular medicine · 2026Review
- Comparison of Percutaneous Coronary Intervention Outcomes for in-Stent vs de Novo Chronic Total Occlusions: A Meta-Analysis.Therapeutics and clinical risk management · 2026Review
- The ApoB/ApoA-I ratio and the risk of in-stent restenosis following drug-eluting stent implantation in patients with coronary heart disease: a retrospective cohort study.Frontiers in cardiovascular medicine · 2026Article
- Symptom Burden in Patients with Acute Coronary Syndrome After Percutaneous Coronary Intervention: A Network and Latent Profile Analysis.Patient preference and adherence · 2026Article
- Article
- Intracoronary Stenting and Restenosis - Randomized Trial of Drug-Eluting Stent Implantation or Drug-Coated Balloon Angioplasty According to Neointima Morphology in Drug-Eluting Stent REstenosis 5: Rationale and Design of the ISAR-DESIRE 5 Trial.Journal of cardiovascular translational research · 2025Article
- Stent Failure Management in Contemporary Clinical Practice.Diagnostics (Basel, Switzerland) · 2025Article
- Effect of Neoatherosclerosis and Intervention-Associated Neoatheroma Rupture on Clinical Outcomes in Patients With In-Stent Restenosis: A Retrospective Study.Health science reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
backgroundIn-stent restenosis (ISR) is highly prevalent and leads to repeat revascularisation. Long-term implications of ISR are poorly understood.
aimsThis study aimed to evaluate the long-term outcomes of patients undergoing percutaneous coronary intervention (PCI) for ISR.
methodsNational Cardiovascular Data Registry CathPCI records for individuals aged ≥65 years undergoing PCI from July 2009 to December 2014 were linked to Medicare claims. Baseline characteristics and long-term rates of death, myocardial infarction (MI), repeat revascularisation including target vessel revascularisation (TVR), and major adverse cardiovascular and cerebrovascular events (MACCE) were compared between ISR PCI versus de novo lesion PCI.
resultsOf 653,304 individuals, 10.2% underwent ISR PCI and 89.8% underwent de novo lesion PCI. The median duration of follow-up was 825 days (quartile 1: 352 days-quartile 3: 1,379 days). The frequency of MACCE (55.6% vs 45.0%; p<0.001), all-cause mortality (27.8% vs 25.5%; p<0.001), MI (19.0% vs 12.3%; p<0.001), repeat revascularisation (31.9% vs 18.6%; p<0.001), TVR (22.4% vs 8.0%; p<0.001), and stroke (8.8% vs 8.3%; p=0.005) was higher after ISR PCI. After multivariable adjustment, ISR PCI remained associated with worse long-term outcomes than after de novo lesion PCI (hazard ratio [HR] for MACCE 1.24 [95% CI: 1.22, 1.26], mortality 1.07 [95% CI: 1.05, 1.09], MI 1.44 [95% CI: 1.40, 1.48], repeat revascularisation 1.55 [95% CI: 1.51, 1.59], and TVR 2.50 [95% CI: 2.42, 2.58]).
conclusionsISR PCI was common and was associated with a significantly higher risk of recurrent long-term major ischaemic events compared to patients undergoing de novo lesion PCI. There remains a need for new strategies to minimise ISR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.